Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22206215 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AROCK2ROCK1TRPV4 | |
| SCHEMBL20811568 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AROCK2ROCK1TRPV4 | |
| Hydrochloric Acid SCHEMBL20791188 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AROCK2ROCK1TRPV4 | |
| Hydrochloric Acid SCHEMBL20791190 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AROCK2ROCK1TRPV4 | |
| SCHEMBL1314596 | 0.85 | ADRB2 (0.72) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL28456091 | 0.79 | ADRB2 (0.52) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL662302 | 0.78 | PGK1 (0.38) | TRPV4KIF11 | |
| SCHEMBL56723 | 0.78 | ADRB2 (0.56) | ADRB2PDE2AMAOAMAOB | |
| SCHEMBL516801 | 0.78 | ADRB2 (0.56) | ADRB2PDE2AMAOAMAOB | |
| SCHEMBL157927 | 0.78 | ADRB2 (0.56) | ADRB2PDE2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245691-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SITRYX THERAPEUTICS LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4330231-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION | Sitryx Therapeutics Limited (GB) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229617-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION | SITRYX THERAPEUTICS LIMITED (GB) | 2022-11-03 | — | — | WO | disclosed |
| EP-2585444-B1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| EP-2585444-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| WO-2011161128-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245691-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | HCAR2, NFKBIA, TNF | ADRB2 502/4885PDE2A 976/4885ROCK2 1114/4885 |
| US-20120190675-A1 | Azaspirohexanones | HSD11B1, HSD3B1, HSD17B1 | ADRB2 280/4885PDE2A 696/4885ROCK2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.